IOVA Q3 2023 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$469,000

Gross Profit

-$4M-825.4% margin

Operating Income

-$118M-25236.9% margin

Net Income

-$114M-24255.9% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

+97.1%

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$88M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$852M

Total Liabilities

$178M

Stockholders' Equity

$674M

Cash & Equivalents

$268M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$469,000	$0	—
Gross Profit	-$4M	$0	—
Operating Income	-$118M	-$100M	-17.9%
Net Income	-$114M	-$100M	-14.2%

Revenue Segments

Product

$500,000100%

Geographic Segments

Non-US

$500,000100%